Scilex Holding Company announced an amendment to its license agreement with Romeg Therapeutics, LLC, securing ex-U.S. rights to Gloperba®.
This amendment expands Scilex's commercialization territory for Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, from solely the U.S. to worldwide rights.
Gloperba® is the first and only liquid oral version of colchicine, offering precise dosing and dose-reduction options for patients, particularly those with renal or hepatic impairment, which is crucial given that gout affects between less than 1% and 6.8% of the population globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.